Santa Clarita Valley residents sometimes like to rail against growth, decrying the paving of what was once pasture.
And while it's true that we do lose some hillsides and scenic beauty to the bulldozers, we also gain some substantial benefits from the valley's growth.
There has been an explosion of new amenities to crop up recently, from hotels and restaurants, to movie theaters and new stores.
It now looks like our growth may have also paid dividends in health care. Santa Clarita was one of 400 locations selected in the United States, Canada and Puerto Rico to be selected to participate in a new breast cancer prevention study for post-menopausal women, it was announced Tuesday.
Researchers will be testing Tamoxifen and Raloxifene to determine if one drug is better than another. In drug studies, some participants are given placebos instead of the experimental medication. In this study, however, women will either get Tamoxifen or Raloxifene, which are both cancer-fighting drugs.
The UCLA/Santa Clarita Valley Cancer Center, on the campus of Henry Mayo Newhall Memorial Hospital, is one of five study sites in Los Angeles County.
The partnership between UCLA and Newhall Memorial is already a boon to valley residents. No longer do Santa Clarita patients have to fight traffic on Interstate 405 to travel down to the university hospital. Instead they can simply drive to HMNMH and visit well-respected specialists without ever leaving the valley.
Now, because UCLA— and the clout that goes with it— is here locally, women will have access to two cancer drugs that they otherwise wouldn't.
Without the partnership between UCLA and Newhall Memorial, it's doubtful the Santa Clarita Valley would have been selected as a testing site.
And without our valley's burgeoning population and the opportunities that go with it, it's doubtful UCLA would have sought to partner with HMNMH.
We do lose some things as our valley grows, but there is also much good that comes out of it.
